170 related articles for article (PubMed ID: 31727921)
1. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.
Marco A; Domínguez-Hernández R; Casado MA
Rev Esp Sanid Penit; 2020; 22(2):66-74. PubMed ID: 32697276
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T
PLoS One; 2021; 16(2):e0245896. PubMed ID: 33571196
[TBL] [Abstract][Full Text] [Related]
14. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
15. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
Chaillon A; Mehta SR; Hoenigl M; Solomon SS; Vickerman P; Hickman M; Skaathun B; Martin NK
PLoS One; 2019; 14(6):e0217964. PubMed ID: 31170246
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015.
Harris AM; Chokoshvili O; Biddle J; Turashvili K; Japaridze M; Burjanadze I; Tsertsvadze T; Sharvadze L; Karchava M; Talakvadze A; Chakhnashvili K; Demurishvili T; Sabelashvili P; Foster M; Hagan L; Butsashvili M; Morgan J; Averhoff F
BMC Public Health; 2019 May; 19(Suppl 3):466. PubMed ID: 32326938
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.
Assoumou SA; Tasillo A; Vellozzi C; Eftekhari Yazdi G; Wang J; Nolen S; Hagan L; Thompson W; Randall LM; Strick L; Salomon JA; Linas BP
Clin Infect Dis; 2020 Mar; 70(7):1388-1396. PubMed ID: 31095676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
